Epileptic Hippocampus in Alzheimer's Disease
NCT05899764, Phase 1, Phase 2, Not yet recruiting, University of California, Los Angeles
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Epileptic Hippocampus in Alzheimer's Disease | ClinicalTrials.gov |
| NCT number | NCT05899764 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1, Phase 2 | ClinicalTrials.gov |
| Enrollment | 25 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of California, Los Angeles | ClinicalTrials.gov |
| Conditions | Alzheimer Disease, Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Brivaracetam | ClinicalTrials.gov |
| First posted | 2023-06-12 | ClinicalTrials.gov |
| Last updated | 2026-01-27 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Brivaracetam on Cognition | 3 months | To determine the efficacy of brivaracetam to improve cognitive function for the following task at 3 months while taking brivaracetam oral tablets: Stroop interference naming (number correct) | ClinicalTrials.gov |
| Primary | Brivaracetam on Cognition | 3 months | To determine the efficacy of brivaracetam to improve cognitive function for the following task at 3 months while taking brivaracetam oral tablets: Virtual Route Learning Test (VRLT) | ClinicalTrials.gov |
| Secondary | Brivaracetam on Cognition | 12 months | To determine the efficacy of brivaracetam to improve cognitive function in the following task while taking brivaracetam oral tablets: Stroop interference naming (number correct) at 6 and 12 months | ClinicalTrials.gov |
| Secondary | Brivaracetam on Cognition | 12 months | To determine the efficacy of brivaracetam to improve cognitive function in the following task while taking brivaracetam oral tablets: Virtual Route Learning Test at 6 and 12 months | ClinicalTrials.gov |
| Secondary | Brivaracetam on Cognition | 12 months | To determine the efficacy of brivaracetam to improve cognitive function in the following task while taking brivaracetam oral tablets: Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at 3, 6, and 12 months (12 month data will be compared to historical data from MCI and AD participants in the Alzheimer's Disease Neuroimaging Initiative) | ClinicalTrials.gov |
| Secondary | Brivaracetam on Functional Decline | 12 months | To compare the rate of decline measured by clinical dementia rating - sum of boxes (CDR-SB) at 12 months while taking brivaracetam to the historical rate of decline in MCI and AD participants collected through the Alzheimer's Disease Neuroimaging Initiative | ClinicalTrials.gov |
| Secondary | Brivaracetam and Plasma Biomarkers | 12 months | To determine whether brivaracetam improves levels of plasma biomarkers of neurodegenerative diseases: Abeta 42/Abeta 40 at 3 months, 6 months, and 12 months while participants take brivaracetam | ClinicalTrials.gov |
| Secondary | Brivaracetam and Plasma Biomarkers | 12 months | To determine whether brivaracetam improves levels of plasma biomarkers of neurodegenerative diseases: total tau at 3 months, 6 months, and 12 month while participants take brivaracetam | ClinicalTrials.gov |
| Secondary | Brivaracetam and Plasma Biomarkers | 12 months | To determine whether brivaracetam improves levels of plasma biomarkers of neurodegenerative diseases: p-tau at 3 months, 6 months, and 12 month while participants take brivaracetam | ClinicalTrials.gov |
| Secondary | Brivaracetam and Plasma Biomarkers | 12 months | To determine whether brivaracetam improves levels of plasma biomarkers of neurodegenerative diseases: GFAP at 3 months, 6 months, and 12 month while participants take brivaracetam | ClinicalTrials.gov |
| Secondary | Brivaracetam and Plasma Biomarkers | 12 months | To determine whether brivaracetam improves levels of plasma biomarkers of neurodegenerative diseases: NfL at 3 months, 6 months, and 12 month while participants take brivaracetam | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 7
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)